AI in life sciences presents key opportunities in drug discovery, personalized medicine, and diagnostics by leveraging vast ...

The National Agency for Food and Drug Administration and Control (NAFDAC) on Thursday, March 12, warned healthcare providers and the public about the circulation of confirmed counterfeit Avastin 400mg ...

Avastin, also known as bevacizumab, is a cancer medicine used in the treatment of recurrent glioblastoma in adults.The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted ...

Several pharmaceutical companies have recently posted encouraging clinical data for their weight-loss candidates. However, most of these won't be approved soon, and Eli Lilly has strong programs of ...

A 40-year partnership of faith, family, and fellowship that grew from Roche Laboratories s to careers in healthcare and ...

The results of the clinical trial mark a setback for the Swiss pharmaceutical company, which saw in the drug, giredestrant, a ...

He is the lead principal investigator of the ALLEGORY study and the lead author and he has also presented the results last Friday at SLEuro. Today, Dr. Richard Furie will take us again through the ...

Shares in Roche fell as much as 8% in early morning trade Monday, amid broad-based losses across European stocks due to the conflict in the Middle East and surging oil prices, before paring back the ...

A new study from researchers led by Johns Hopkins Medicine reports substantial new evidence that elevated blood biomarkers of subclinical heart injury or stress — heart muscle damage without symptoms ...

Women with certain cardiometabolic risk factors, including type 2 diabetes and high waist circumference, face a greater increase in risk for liver fibrosis than men with the same risk factors. The ...

Investors who want to capitalize on the growing weight loss market might be tempted to turn to the current leaders in the ...

Zealand and Roche are jointly developing the drug petrelintide which in a mid-stage study led to a worse-than-expected 10.7% ...